CO2017011813A2 - Métodos para inhibir genes de señalización por hipoxia empleando ape-1/ref-1 como objetivo - Google Patents

Métodos para inhibir genes de señalización por hipoxia empleando ape-1/ref-1 como objetivo

Info

Publication number
CO2017011813A2
CO2017011813A2 CONC2017/0011813A CO2017011813A CO2017011813A2 CO 2017011813 A2 CO2017011813 A2 CO 2017011813A2 CO 2017011813 A CO2017011813 A CO 2017011813A CO 2017011813 A2 CO2017011813 A2 CO 2017011813A2
Authority
CO
Colombia
Prior art keywords
ref
ape
methods
target
signaling genes
Prior art date
Application number
CONC2017/0011813A
Other languages
English (en)
Inventor
Mark R Kelley
Melissa Fishel
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57320327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017011813(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of CO2017011813A2 publication Critical patent/CO2017011813A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Resumen Se divulgan métodos para emplear endonucleasa apurínica/apirimidínica-1/factor efector redox-1 (APE-l/Ref-1) como objetivo. Más particularmente, se divulgan métodos para inhibir APE-l/Ref-1 y señalización mediada por hipoxia para disminuir supervivencia e invasión de células tumorales expuestas a condiciones hipóxicas.
CONC2017/0011813A 2015-05-21 2017-11-21 Métodos para inhibir genes de señalización por hipoxia empleando ape-1/ref-1 como objetivo CO2017011813A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562164795P 2015-05-21 2015-05-21
US201662307000P 2016-03-11 2016-03-11
PCT/US2016/030904 WO2016186853A1 (en) 2015-05-21 2016-05-05 Methods of targeting ape1/ref-1 to inhibit hypoxia signaling genes

Publications (1)

Publication Number Publication Date
CO2017011813A2 true CO2017011813A2 (es) 2018-02-09

Family

ID=57320327

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0011813A CO2017011813A2 (es) 2015-05-21 2017-11-21 Métodos para inhibir genes de señalización por hipoxia empleando ape-1/ref-1 como objetivo

Country Status (16)

Country Link
US (1) US10772859B2 (es)
EP (1) EP3297623B1 (es)
JP (1) JP6862355B2 (es)
KR (1) KR20180010245A (es)
CN (1) CN107708682A (es)
AU (1) AU2016262985B2 (es)
BR (1) BR112017024552A2 (es)
CA (1) CA2986248C (es)
CL (1) CL2017002942A1 (es)
CO (1) CO2017011813A2 (es)
IL (1) IL255611A (es)
MX (1) MX2017014750A (es)
PH (1) PH12017502121A1 (es)
RU (1) RU2017144823A (es)
WO (1) WO2016186853A1 (es)
ZA (1) ZA201707735B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020505457A (ja) * 2017-01-23 2020-02-20 ユニヴァーシティ オブ ハワイＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｈａｗａｉｉ ２−アリールスルホンアミド−Ｎ−アリールアセトアミド誘導体化Ｓｔａｔ３
US20190365689A1 (en) * 2017-01-25 2019-12-05 Indiana University Research And Technology Corporation Use of ape/ref-1 redox specific inhibitors for treating metastatic prostate cancer
WO2018140286A1 (en) * 2017-01-25 2018-08-02 Indiana University Research And Technology Corporation Prophylaxis and treatment of acute myeloid leukemia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI102273B (fi) * 1989-09-11 1998-11-13 Eisai Co Ltd Kinonijohdannaiset, niiden valmistaminen ja niiden farmakologinen käyt tö
WO2007089878A2 (en) * 2006-01-31 2007-08-09 Angiotech Pharmaceuticals, Inc. Sutures and anti-scarring agents
KR101689796B1 (ko) 2007-09-26 2016-12-27 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 암 및 혈관신생의 치료를 위하여 화학요법제와 병용하는 벤조퀴논 유도체 ｅ３３３０
CN103221388B (zh) 2010-07-09 2016-09-28 维理生物技术公司 用于抑制转移性肿瘤生长的新型磺酰胺化合物
MX356102B (es) 2012-03-14 2018-05-14 Univ Indiana Res & Tech Corp Compuestos y métodos para tratar leucemia.
US20150065447A1 (en) 2013-08-20 2015-03-05 Incyte Corporation Survival benefit in patients with solid tumors with elevated c-reactive protein levels
JP2016533752A (ja) 2013-08-28 2016-11-04 カリス ライフ サイエンシズ スウィッツァーランド ホー オリゴヌクレオチドプローブおよびその使用

Also Published As

Publication number Publication date
CA2986248C (en) 2023-09-26
US20180200213A1 (en) 2018-07-19
CA2986248A1 (en) 2016-11-24
BR112017024552A2 (pt) 2018-07-24
AU2016262985B2 (en) 2021-02-25
WO2016186853A1 (en) 2016-11-24
KR20180010245A (ko) 2018-01-30
AU2016262985A1 (en) 2017-12-07
JP2018515546A (ja) 2018-06-14
EP3297623A4 (en) 2019-04-10
MX2017014750A (es) 2018-02-09
US10772859B2 (en) 2020-09-15
CL2017002942A1 (es) 2018-04-13
EP3297623A1 (en) 2018-03-28
CN107708682A (zh) 2018-02-16
ZA201707735B (en) 2018-11-28
JP6862355B2 (ja) 2021-04-21
PH12017502121A1 (en) 2018-05-28
EP3297623B1 (en) 2020-10-28
IL255611A (en) 2018-01-31
RU2017144823A (ru) 2019-06-24

Similar Documents

Publication Publication Date Title
HK1252351A1 (zh) 經修飾的因子ix、以及用於基因轉移到細胞、器官和組織的組合物、方法和用途
CL2016002394A1 (es) Derivados de quinolina como inhibidores de smo
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
ECSP17072474A (es) Métodos para tratar infecciones por el virus filoviridae
MX2018006578A (es) Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias.
EP3371314A4 (en) GENOMIC MANIPULATION OF PLURIPOTENTIAL CELLS
MX2018006148A (es) Inhibidores de cxcr2.
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
NZ732799A (en) Picolinamides with fungicidal activity
CU20150119A7 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AU2015374459A8 (en) Picolinamide compounds with fungicidal activity
EP3129493A4 (en) Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
MX2021014663A (es) Il-23a y tnf-alfa orientados y compuesto y sus usos.
EP3268125A4 (en) Determination of cells using amplification
IL254385A0 (en) Devices and methods for using a cell division site to control cell division
CO2017011813A2 (es) Métodos para inhibir genes de señalización por hipoxia empleando ape-1/ref-1 como objetivo
PH12019501224A1 (en) Compositions for treatment of polycystic kidney disease
MX2022001801A (es) Secuencias recombinantes de cromosoma b de maiz y sus usos.
MY187959A (en) Reactor
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
EP3288378A4 (en) Use of tree sap to preserve sperm cell lines
GB201511482D0 (en) Culture of RPE cells
EP3621603A4 (en) HYDROXYUREA SERVING TO IMPROVE SPERMATIC CELLS
UY36086A (es) Compuestos de quinoxalina y usos de los mismos